Top 5 Stocks to Buy Now
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:BGMS

Cyclacel Pharmaceuticals Q1 2026 Earnings Report

Cyclacel Pharmaceuticals logo
$0.60 -0.04 (-5.57%)
Closing price 03:59 PM Eastern
Extended Trading
$0.63 +0.03 (+5.11%)
As of 05:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Cyclacel Pharmaceuticals EPS Results

Actual EPS
-$0.04
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Cyclacel Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cyclacel Pharmaceuticals Announcement Details

Quarter
Q1 2026
Date
5/15/2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Cyclacel Pharmaceuticals Earnings Headlines

Head-To-Head Contrast: Kailera Therapeutics (NASDAQ:KLRA) versus Cyclacel Pharmaceuticals (NASDAQ:BGMS)
June 25 at 5:01 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30860925
Bio Green Med Solution Surges 172% After Announcing Deal to Acquire Malaysia Waste Tech Company
June 5, 2026  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/26/06/53027103/bio-green-med-solution-surges-172-after-announcing-deal-to-acquire-malaysia-waste-tech-company?utm_source=snapi
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel
June 25 at 1:00 AM  |  Reagan Gold Group (Ad)
BGMS Stock Alert: Halper Sadeh LLC is Investigating Whether Bio Green Med Solution, Inc. is Obtaining a Fair Price for its Shareholders
June 4, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260604673036/en/bgms-stock-alert-halper-sadeh-llc-is-investigating-whether-bio-green-med-solution-inc.-is-obtaining-a-fair-price-for-its-shareholders/
BIO GREEN MED SOLUTION, INC. ANNOUNCES BUSINESS COMBINATION AGREEMENT TO ACQUIRE FUTURE NRG SDN.
June 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/04/3307097/0/en/bio-green-med-solution-inc-announces-business-combination-agreement-to-acquire-future-nrg-sdn-bhd.html
BIO GREEN MED SOLUTION REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
May 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/14/3295402/0/en/bio-green-med-solution-reports-first-quarter-financial-results-and-provides-business-update.html
See More Cyclacel Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cyclacel Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cyclacel Pharmaceuticals and other key companies, straight to your email.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals (NASDAQ:BGMS) is a clinical-stage biopharmaceutical company that focuses on developing small-molecule therapies that target the cell cycle and related regulatory pathways for the treatment of cancer and other proliferative diseases. The company's research and development efforts center on kinase and cell-cycle inhibitors designed to disrupt tumor growth and induce cancer cell death. Cyclacel advances programs through preclinical development and clinical trials with the aim of delivering new therapeutic options for patients with solid tumors and hematologic malignancies.

Key activities at Cyclacel include in-house drug discovery, translational research, and the clinical development of lead candidate molecules. One of the company’s best-known programs is fadraciclib (also known as CYC065), a cyclin-dependent kinase inhibitor that has been investigated in clinical studies for multiple cancer indications. Beyond individual assets, Cyclacel’s pipeline reflects a strategy of pursuing mechanistically driven compounds that can be combined with standard-of-care therapies or other targeted agents to improve clinical outcomes.

Cyclacel conducts clinical development activities and collaborates with research institutions and potential industry partners to support its programs and expand clinical testing across multiple jurisdictions. As a publicly traded company, Cyclacel engages with the investor and scientific communities to communicate progress on its development milestones. Management and scientific leadership are focused on progressing late-stage preclinical work and clinical studies while exploring partnerships to advance commercialization pathways for its therapeutics.

View Cyclacel Pharmaceuticals Profile
Earnings Tools